alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 12.1

ViroPharma Incorporated

Schedule of Ratio of Earnings to Fixed Charges



|                                                      |  |            |  |             |   |  |             |   |  |             |   |  |             |  
|----------------------------------------------------- |  | ---------- |  | ----------- | - |  | ----------- | - |  | ----------- | - |  | ----------- | -
|                                                      |  | 2005       |  | 2004        |   |  | 2003        |   |  | 2002        |   |  | 2001        |  
|Net Income (Loss) from continuing operations          |  | 65,129,838 |  | (19,533,326 | ) |  | (36,941,939 | ) |  | (26,622,883 | ) |  | (78,481,204 | )
|Add:                                                  |  |            |  |             |   |  |             |   |  |             |   |  |             |  
|Fixed charges                                         |  | 11,568,499 |  | 10,653,814  |   |  | 8,998,923   |   |  | 11,434,451  |   |  | 11,978,112  |  
|                                                      |  |            |  |             |   |  |             |   |  |             |   |  |             |  
|Earnings as adjusted                                  |  | 76,698,337 |  | (8,879,512  | ) |  | (27,943,016 | ) |  | (15,188,432 | ) |  | (66,503,092 | )
|                                                      |  |            |  |             |   |  |             |   |  |             |   |  |             |  
|Fixed Charges:                                        |  |            |  |             |   |  |             |   |  |             |   |  |             |  
|Interest (gross)                                      |  | 10,322,838 |  | 8,950,190   |   |  | 7,825,657   |   |  | 10,248,483  |   |  | 10,800,693  |  
|Portion of rent representative of the interest factor |  | 264,479    |  | 334,539     |   |  | 561,376     |   |  | 400,253     |   |  | 358,962     |  
|Amortization of debt issuance costs                   |  | 981,182    |  | 1,369,085   |   |  | 611,890     |   |  | 785,715     |   |  | 818,457     |  
|                                                      |  |            |  |             |   |  |             |   |  |             |   |  |             |  
|Total fixed charges                                   |  | 11,568,499 |  | 10,653,814  |   |  | 8,998,923   |   |  | 11,434,451  |   |  | 11,978,112  |  
|                                                      |  |            |  |             |   |  |             |   |  |             |   |  |             |  
|Deficiency of earnings to cover fixed charges         |  | N/A        |  | 19,533,326  |   |  | 36,941,939  |   |  | 26,622,883  |   |  | 78,481,204  |  
|                                                      |  |            |  |             |   |  |             |   |  |             |   |  |             |
§ 876.5630 Peritoneal dialysis system and accessories. ( a ) *Identification.* ( 1 ) A peritoneal dialysis system and accessories is a device that is used as an artificial kidney system for the treatment of patients with renal failure or toxemic conditions, and that consists of a peritoneal access device, an administration set for peritoneal dialysis, a source of dialysate, and, in some cases, a water purification mechanism. After the dialysate is instilled into the patient's peritoneal cavity, it is allowed to dwell there so that undesirable substances from the patient's blood pass through the lining membrane of the peritoneal cavity into this dialysate. These substances are then removed when the dialysate is drained from the patient. The peritoneal dialysis system may regulate and monitor the dialysate temperature, volume, and delivery rate together with the time course of each cycle of filling, dwell time, and draining of the peritoneal cavity or manual controls may be used. This generic device includes the semiautomatic and the automatic peritoneal delivery system.
( 2 ) The peritoneal access device is a flexible tube that is implanted through the abdominal wall into the peritoneal cavity and that may have attached cuffs to provide anchoring and a skin seal. The device is either a single use peritioneal catheter, intended to remain in the peritoneal cavity for less than 30 days, or a long term peritoneal catheter. Accessories include stylets and trocars to aid in the insertion of the catheter and an obturator to maintain the patency of the surgical fistula in the abdominal wall between treatments.
( 3 ) The disposable administration set for peritoneal dialysis consists of tubing, an optional reservoir bag, and appropriate connectors. It may include a peritoneal dialysate filter to trap and remove contaminating particles.
( 4 ) The source of dialysate may be sterile prepackaged dialysate (for semiautomatic peritoneal dialysate delivery systems or “cycler systems”) or dialysate prepared from dialysate concentrate and sterile purified water (for automatic peritoneal dialysate delivery systems or “reverse osmosis” systems). Prepackaged dialysate intended for use with either of the peritoneal dialysate delivery systems is regulated by FDA as a drug.
( b ) *Classification.* Class II (special controls). The following accessories are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9: A catheter finger grip that is non-patient contacting and intended for single use with a peritoneal catheter; a continuous ambulatory peritoneal dialysis (CAPD) belt; and a catheter stand that does not include weigh scales.
[48 FR 53023, Nov. 23, 1983, as amended at 84 FR 71814, Dec. 30, 2019]
#### § 640.55 U.S. Standard preparation.

A U.S. Standard Antihemophilic Factor (Factor VIII) preparation may be obtained from the Center for Biologics Evaluation and Research, (HFM-407) (see mailing addresses in § 600.2 of this chapter) for use in the preparation of a working reference to be employed in a quality control potency test of Cryoprecipitated AHF.

[42 FR 21774, Apr. 29, 1977, as amended at 49 FR 23834, June 8, 1984; 50 FR 4140, Jan. 29, 1985; 55 FR 11013, Mar. 26, 1990; 70 FR 14985, Mar. 24, 2005]
<TABLE> <S> <C>


<ARTICLE>                     5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                              DEC-31-1997
<PERIOD-START>                                 JAN-01-1997
<PERIOD-END>                                   SEP-30-1997
<CASH>                                           6,483,930
<SECURITIES>                                    62,106,859
<RECEIVABLES>                                    7,877,679
<ALLOWANCES>                                             0
<INVENTORY>                                      9,485,513
<CURRENT-ASSETS>                                90,231,344
<PP&E>                                           1,687,702
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                  93,561,668
<CURRENT-LIABILITIES>                            7,881,940
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                           192,946
<OTHER-SE>                                      85,486,782
<TOTAL-LIABILITY-AND-EQUITY>                    93,561,668
<SALES>                                         45,631,043
<TOTAL-REVENUES>                                45,631,043
<CGS>                                           14,598,201
<TOTAL-COSTS>                                   23,850,037
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                  9,443,438
<INCOME-TAX>                                     2,950,000
<INCOME-CONTINUING>                              6,493,438
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                     6,493,438
<EPS-PRIMARY>                                         0.33
<EPS-DILUTED>                                         0.33
        


</TABLE>
§ 803.17 What are the requirements for developing, maintaining, and implementing written MDR procedures that apply to me? If you are a user facility, importer, or manufacturer, you must develop, maintain, and implement written MDR procedures for the following: ( a ) Internal systems that provide for: ( 1 ) Timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements;
( 2 ) A standardized review process or procedure for determining when an event meets the criteria for reporting under this part; and
( 3 ) Timely transmission of complete medical device reports to manufacturers or to us, or to both if required.
( b ) Documentation and recordkeeping requirements for: ( 1 ) Information that was evaluated to determine if an event was reportable;
( 2 ) All medical device reports and information submitted to manufacturers and/or us;
( 3 ) Any information that was evaluated for the purpose of preparing the submission of annual reports; and
( 4 ) Systems that ensure access to information that facilitates timely followup and inspection by us.
§ 558.470 Polyoxyethylene. ( a ) *Specifications.* Each molasses-based block contains 2.2 percent polyoxyethylene (23) lauryl ether.
( b ) *Sponsor.* See No. 067949 in § 510.600(c) of this chapter.
( c ) [Reserved]
( d ) *Conditions of use* — ( 1 ) *Amount.* 2 grams of polyoxyethylene (23) lauryl ether per 100 kilograms of body weight per day (1 pound of block per 500 kilogram (1,100 pound) animal per day). Initially, provide one block per five head of cattle. Start treatment 10 to 14 days before exposure to bloat-producing pastures.
( 2 ) *Indications for use.* For reduction of the incidence of bloat (alfalfa and clover) in pastured cattle.
( 3 ) *Limitations.* Administer free-choice to beef cattle and nonlactating dairy cattle only. Do not allow cattle access to other sources of salt while being fed this product. Do not feed this product to animals without adequate forage/roughage consumption.
[86 FR 14826, Mar. 19, 2021]
POST FOCUS EXPOSURE REPORT

Case Number: P040141 Assessor: Wormell

ENVIRONMENTAL RELEASES

Scenario#: 1 Number of Release Sites: 

Release Activity:

Release Description: WATER LANDFILL INCINER LAND/INCIN FUGITIVE

Total Releases:

(kg/yr) (kg/yr) (kg/yr) (kg/yr) (kg/yr)

Release Days/yr:

Per Site Release:

(kg/day) (kg/yr) (kg/yr) (kg/yr) (kg/day)

Remarks: Revised engineer report (04/15/04)

Consumer use expected?
POST FOCUS EXPOSURE REPORT

CASE NUMBER:P040141
POST FOCUS EXPOSURE REPORT

CASE NUMBER: P040141
POST FOCUS EXPOSURE REPORT

Case Number: P040141 Assessor: Wormell

ENVIRONMENTAL RELEASES

Scenario#: 2 Number of Release Sites: 

Release Activity:

Release Description: WATER LANDFILL INCINER LAND/INCIN FUGITIVE

Total Releases:

(kg/yr) (kg/yr) (kg/yr) (kg/yr) (kg/yr)

Release Days/yr: 

Per Site Release:

(kg/day) (kg/yr) (kg/yr) (kg/yr) (kg/day)

Remarks: Revised engineer report (04/15/04)

 
POST FOCUS EXPOSURE REPORT

Case Number: P040141 Assessor: Wormell

ENVIRONMENTAL RELEASES

Scenario#: 3 Number of Release Sites: 

Release Activity:

Release Description: WATER LANDFILL INCINER LAND/INCIN FUGITIVE

Total Releases:

(kg/yr) (kg/yr) (kg/yr) (kg/yr) (kg/yr)

Release Days/yr: 

Per Site Release:

(kg/day) (kg/yr) (kg/yr) (kg/yr) (kg/day)

Remarks:

 
POST FOCUS EXPOSURE REPORT

CASE NUMBER:P040141
EXHIBIT 32

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GVC Venture Corp. (the "Company") on
Form 10-QSB for the quarter ended March 31, 2005, as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Bernard Zimmerman,
Principal Executive Officer and Principal Financial Officer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 that, to the best of my knowledge:

         (1)      The Report fully complies with the requirements of Section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2)      The information contained in the report fairly presents, in
                  all material respects, the financial condition and results of
                  operations of the Company.

May 11, 2005

                                              /s/ Bernard Zimmerman
                                              ----------------------------------
                                              Bernard Zimmerman, President
                                              (Principal Executive Officer) and
                                              Treasurer (Principal Financial and
                                              Accounting Officer)
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.3680 Nose prosthesis. ( a ) *Identification.* A nose prosthesis is a silicone rubber solid device intended to be implanted to augment or reconstruct the nasal dorsum.
( b ) *Classification.* Class II.
(logo)**Prudential**

**PrudentialAsset Resources**

PrudentialMortgage Capital Company

2100Ross Avenue, Suite 2500, Dallas TX 75201

Tel214-777-4500

 

Abusiness of Prudential Financial, Inc.

 

WellsFargo Bank, National Association

CommercialMortgage Servicing

MACD1086

550South Tryon Street, 14th Floor

Charlotte,North Carolina 28202

Attention:Asset Manager

 

** **

**RE:WFCM 2015-SGl**

**Period:January 1, 2017 to December 31, 2017(the "Reporting Period")**

 

**Annual ComplianceStatement**

 

I,Joni Brown-Haas, in my capacity as President and Managing Director ofPrudential Asset Resources, Inc. (the "Company") hereby certify withregard to the Company's role as Sub-Servicer under the Sub-Servicing Agreement,(the "Agreement") dated as of August 1, 2015, pertaining to theabove-referenced certificates, that:

 

(i)a review of the activities of the Company under the Agreement  during theperiod noted above, and of the performance of the Company under the Agreementduring the reporting period has been made under my supervision, and

 

(ii)to the best of my knowledge, based on such review, the Company has fulfilledall its obligations under the Agreement throughout the reporting period, and

 

(iii)to the best of my knowledge, based on such review, the Company has fulfilledits obligations under its sub-servicing agreement in all material respects, and

 

(iv)the Company has maintained an effective internal control system over theservicing of mortgage loans including the Loans serviced by the Company, and

 

(v)the Company has not received any notice regarding qualification, or challengingthe status of the Lower Tier REMIC or the Upper Tier REMIC as a REMIC, from theIRS or any other governmental agency or body.

 

 

Effectiveas of 2/22/2018

 

 

/s/Joni Brown-Haas

JoniBrown‐Haas

Presidentand Managing Director 

PrudentialAsset Resources, Inc.
<PAGE>   1



                                                                      EXHIBIT 13

   INDEPENDENT PUBLIC ACCOUNTANTS' REVIEW REPORT


   To the Board of Directors and Shareholders of
   Essef Corporation
   Chardon, Ohio


   We have reviewed the accompanying condensed consolidated balance sheet of
   Essef Corporation and Subsidiaries (the "Company") as of December 31, 1998,
   and the related condensed consolidated statements of income and cash flows
   for the three-month periods ended December 31, 1998 and 1997. These financial
   statements are the responsibility of the Company's management.

   We conducted our reviews in accordance with standards established by the
   American Institute of Certified Public Accountants. A review of interim
   financial information consists principally of applying analytical procedures
   to financial data and making inquiries of persons responsible for financial
   and accounting matters. It is substantially less in scope than an audit
   conducted in accordance with generally accepted auditing standards, the
   objective of which is the expression of an opinion regarding the financial
   statements taken as a whole. Accordingly, we do not express such an opinion.

   Based on our reviews, we are not aware of any material modifications that
   should be made to such condensed consolidated financial statements for them
   to be in conformity with generally accepted accounting principles.

   We have previously audited, in accordance with generally accepted auditing
   standards, the consolidated balance sheet of the Company as of September 30,
   1998, and the related consolidated statements of income, shareholders'
   equity, and cash flows for the year then ended (not presented herein) and in
   our report dated November 13, 1998, we expressed an unqualified opinion on
   those consolidated financial statements. In our opinion, the information set
   forth in the accompanying condensed consolidated balance sheet as of
   September 30, 1998 is fairly stated, in all material respects, in relation to
   the consolidated balance sheet from which it has been derived.


   DELOITTE & TOUCHE LLP

   Cleveland, Ohio
   January 25, 1999
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5675 Rebreathing device. ( a ) *Identification.* A rebreathing device is a device that enables a patient to rebreathe exhaled gases. It may be used in conjunction with pulmonary function testing or for increasing minute ventilation.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 868.9.
[47 FR 31142, July 16, 1982, as amended at 65 FR 2313, Jan. 14, 2000]
GLOBAL INTELLICOM, INC. AND SUBSIDIARIES

                                   EXHIBIT 11

                       COMPUTATION OF EARNINGS PER SHARE


<TABLE>
<CAPTION>

                                                                            YEAR ENDED DECEMBER 31,
                                                                  1997                1996                1995
<S>                                                           <C>                  <C>                  <C>                   
BASIC INCOME PER COMMON SHARE INCOME:
         Income (loss) from continuing operations             ($2,302,808)         ($706,493)           $203,332
         Less:
         Dividends                                                188,673                 --                  --
                                                                             
         Cumulative undeclared dividend on Series 3
         Convertible Preferred Stock                               61,250             61,250                  --

         Dividends deemed from beneficial conversion
         features of preferred stock                              400,000          3,376,374                  --
                                                               ----------         ----------            --------
         Adjusted income (loss) from continuing
         operations                                           ($2,952,731)       ($4,144,117)           $203,332
                                                               ==========         ==========            ========

         Discontinued operations                              ($7,133,152)         ($378,895)            $66,851
                                                               ==========         ==========            ========
SHARES:
         Weighted average number of common shares
         outstanding                                            7,481,307          3,527,053           2,927,170
                                                               ==========         ==========           =========

BASIC INCOME (LOSS) PER COMMON SHARE:
         Income (loss) from continuing operations                  ($0.40)            ($1.17)              $0.07
         Discontinued operations                                    (0.95)             (0.11)               0.02
                                                                    -----              -----               -----
                                                                   ($1.35)            ($1.28)              $0.09
                                                                    =====              =====               =====

</TABLE>

NOTE: Diluted earnings per share was not calculated as the Company incurred 
losses from continuing operations in 1997 and 1996 and the inclusion of common 
stock equivalents, etc. would be antidilutive. In 1997 and 1996, the 
potentially dilutive securities included various series of convertible stock as
well as various warrants and stock options. In 1995, the Company did not have 
any potentially dilutive securities.


                                      F-47
# C_2016027EN.01005601.xml

| 25.1.2016 | EN | Official Journal of the European Union | C 27/56 |
| --- | --- | --- | --- |

25.1.2016

EN

Official Journal of the European Union

C 27/56

---

Order of the General Court of 23 November 2015 — Beul v Parliament and Council

(Case T-640/14) (1)

1

((Action for annulment - Functioning of financial markets - Regulation (EU) No 537/2014 - Legislative act - Lack of individual concern - Inadmissibility))

(2016/C 027/72)

Language of the case: German

Parties

Parties

Applicant: Carsten René Beul (Neuwied, Germany) (represented initially by K.-G Stümper, then by H.-M. Pott and T. Eckhold, lawyers)

Applicant:

Defendants: European Parliament (represented by: P. Schonard and D. Warin, acting as Agents) and Council of the European Union (represented by R. Weimann and N. Rouam, acting as Agents)

Defendants:

Re:

Re:

Application for annulment of Regulation (EU) No 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC (OJ 2014 L 158, p. 77).

Operative part of the order

Operative part of the order

| 1. | The action is dismissed as inadmissible. |
| --- | --- |

1.

The action is dismissed as inadmissible.

| 2. | There is no need to adjudicate on the European Commission’s application for leave to intervene. |
| --- | --- |

2.

There is no need to adjudicate on the European Commission’s application for leave to intervene.

| 3. | Mr Carsten René Beul shall bear his own costs and shall pay those incurred by the European Parliament and the Council of the European Union. |
| --- | --- |

3.

Mr Carsten René Beul shall bear his own costs and shall pay those incurred by the European Parliament and the Council of the European Union.

| 4. | The Commission and the Parliament shall bear their own costs relating to the application to intervene. |
| --- | --- |

4.

The Commission and the Parliament shall bear their own costs relating to the application to intervene.

---

(1)  OJ C 409, 17.11.2014.

1

---
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.5150 Embolectomy catheter. ( a ) *Identification.* An embolectomy catheter is a balloon-tipped catheter that is used to remove thromboemboli, i.e., blood clots which have migrated in blood vessels from one site in the vascular tree to another.
( b ) *Classification.* Class II (performance standards).